Comparative Pharmacology
Head-to-head clinical analysis: GVS versus NETROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus NETROMYCIN.
GVS vs NETROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Netromycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in bacteria.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
4-6 mg/kg IV once daily for serious infections; 1.5-2 mg/kg IV every 8 hours for gram-negative infections. Administered as intravenous infusion over 30-60 minutes.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 2-3 hours in adults with normal renal function, but may extend to 24-48 hours in patients with impaired renal function.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic